792 results match your criteria Pityriasis Rubra Pilaris


[Pityriasis rubra pilaris: 3 cases with biologics].

Ann Dermatol Venereol 2019 Mar 28. Epub 2019 Mar 28.

Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2019.01.020DOI Listing
March 2019
1 Read

Systemische Therapien bei Pityriasis rubra pilaris: eine systematische Übersicht.

J Dtsch Dermatol Ges 2019 03;17(3):243-260

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Göttingen, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13718_gDOI Listing
March 2019
2 Reads

Successful treatment of TNFα inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin.

Eur J Dermatol 2019 Mar 2. Epub 2019 Mar 2.

Department of Dermatology, Edouard-Herriot Hospital, Lyon I University, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2019.3502DOI Listing
March 2019
1 Read

Pityriasis Rubra Pilaris.

Authors:
A Brooke Eastham

JAMA Dermatol 2019 Feb 6. Epub 2019 Feb 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.5030DOI Listing
February 2019
1 Read

Pityriasis Rubra Pilaris: A Study Evaluating Patient Quality of Life in Two Populations.

J Am Acad Dermatol 2019 Jan 30. Epub 2019 Jan 30.

Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622193017
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2019.01.061DOI Listing
January 2019
13 Reads

The management and genetic background of pityriasis rubra pilaris: a single-centre experience.

J Eur Acad Dermatol Venereol 2019 Jan 29. Epub 2019 Jan 29.

Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.

Background: Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory dermatosis with multifactorial aetiology. It is known that particular caspase recruitment domain family member 14 (CARD14) gene mutations are associated with familial PRP and certain forms of psoriasis. Additionally, few data are available about the role of CARD14 gene variants in sporadic PRP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15455DOI Listing
January 2019
1 Read

[The very first images in the Annales de dermatologie et de syphiligraphie, 1868-1889].

Authors:
B Cribier

Ann Dermatol Venereol 2018 Dec;145 Suppl 6:VIS63-VIS100

Clinique dermatologique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67091 Strasbourg cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0151-9638(18)31295-XDOI Listing
December 2018
4 Reads

Systemic therapies of pityriasis rubra pilaris: a systematic review.

J Dtsch Dermatol Ges 2019 Mar 6;17(3):243-259. Epub 2018 Dec 6.

Department of Dermatology, Venereology, and Allergology, University Medical Centre, Göttingen, Germany.

Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder. Treatment is challenging; the armamentarium consists of topical corticosteroids, phototherapy, classic systemic treatments such as retinoids or immunosuppressive drugs, and most recently biologicals. However, the relative effectiveness of therapies is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13718DOI Listing
March 2019
4 Reads

Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40.

J Dermatol 2019 Jan 3;46(1):70-72. Epub 2018 Dec 3.

Department of Dermatology, Kansai Medical University, Hirakata, Japan.

We report herein a case of a 72-year-old man with pityriasis rubra pilaris (PRP) that was refractory to conventional therapies. His skin lesions progressed to generalized erythroderma despite anti-interleukin (IL)-17A antibody therapy. Topical corticosteroids, emollients, systemic retinoid, methotrexate, cyclosporin and phototherapy yielded no therapeutic response. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1346-8138.14709
Publisher Site
http://dx.doi.org/10.1111/1346-8138.14709DOI Listing
January 2019
16 Reads

Dermoscopy of Juvenile Circumscribed Pityriasis Rubra Pilaris.

Indian Dermatol Online J 2018 Nov-Dec;9(6):474-476

Department of Dermatology and Venereology, Pramukhswami Medical College, Karamsad, Gujarat, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_334_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233002PMC
December 2018
3 Reads

Atypical Adult-Onset Pityriasis Rubra Pilaris in an HIV-Positive Adult Male.

Indian J Dermatol 2018 Nov-Dec;63(6):522-524

Department of Dermatology and Venereology, Pramukhswami Medical College, Karamsad, Gujarat, India. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_141_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233044PMC
December 2018
12 Reads

Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy.

Dermatol Pract Concept 2018 Oct 31;8(4):299-302. Epub 2018 Oct 31.

Department of Skin & VD, Patna Medical College and Hospital, Patna, Bihar, India.

Background: Diagnosing and differentiating pityriasis rubra pilaris (PRP) from other disorders can be a challenging task. Although histopathology remains the gold standard, it may not be feasible at times, especially in children. Being noninvasive, dermoscopy can be of great diagnostic importance in such a scenario. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5826/dpc.0804a10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246058PMC
October 2018
6 Reads

Clinical and Genetic Heterogeneity of Mutations in Psoriatic Skin Disease.

Front Immunol 2018 16;9:2239. Epub 2018 Oct 16.

Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.

The CARD: BCL10: MALT1 (CBM) complex is an essential signaling node for maintaining both innate and adaptive immune responses. CBM complex components have gained considerable interest due to the dramatic effects of associated mutations in causing severe lymphomas, immunodeficiencies, carcinomas and inflammatory disease. While MALT1 and BCL10 are ubiquitous proteins, the CARD-containing proteins differ in their tissue expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198054PMC
October 2018
2 Reads

Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases.

JAAD Case Rep 2018 Oct 10;4(9):944-946. Epub 2018 Oct 10.

Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.07.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191946PMC
October 2018
2 Reads

A Practical Approach to the Diagnosis and Treatment of Adult Erythroderma.

Actas Dermosifiliogr 2018 Nov 10;109(9):777-790. Epub 2018 Oct 10.

Departamento de Dermatología, Universidad Autónoma de Nuevo León, Hospital Universitario «Dr. José E. González» y Facultad de Medicina, Monterrey, México. Electronic address:

Erythroderma is an inflammatory skin syndrome that involves desquamation and erythema of more than 90% of the body surface area. It represents a final clinical endpoint for many adult dermatological conditions. The most frequent cause of erythroderma is psoriasis followed by eczematous conditions, drug-induced reactions, pityriasis rubra pilaris and cutaneous T-cell lymphomas. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00017310183033
Publisher Site
http://dx.doi.org/10.1016/j.ad.2018.05.011DOI Listing
November 2018
30 Reads

Successful treatment of type I pityriasis rubra pilaris with ixekizumab.

JAAD Case Rep 2018 Sep 14;4(8):774-776. Epub 2018 Sep 14.

Creighton University School of Medicine, Omaha, Nebraska.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.05.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141639PMC
September 2018
1 Read

Successful treatment of erythrodermic pityriasis rubra pilaris with acitretin.

Dermatol Ther 2018 09 19;31(5):e12694. Epub 2018 Sep 19.

Anatomopathology, Department of Surgical Science, University of Cagliari, Cagliari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12694DOI Listing
September 2018
4 Reads

Distinguishing histopathologic features of acantholytic dermatoses and the pattern of acantholytic hypergranulosis.

J Cutan Pathol 2019 Jan 5;46(1):6-15. Epub 2018 Nov 5.

Department of Dermatology, University of California San Francisco, San Francisco, California.

Background: Acantholysis can be seen in multiple skin diseases. Adnexal acantholysis has been regarded as a feature distinguishing pemphigus vulgaris (PV) from acantholytic conditions.

Methods: A retrospective review of the histopathologic features of diseases with acantholysis including PV, pemphigus foliaceus (PF), Hailey-Hailey disease (HHD), Darier disease (DD), Grover disease, and pityriasis rubra pilaris (PRP) was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13356DOI Listing
January 2019
5 Reads

Dermatoscopy and Reflectance Confocal Microscopy Correlations in Nonmelanocytic Disorders.

Dermatol Clin 2018 Oct 16;36(4):487-501. Epub 2018 Aug 16.

Dermatology Clinic, University of Catania, Via Santa Sofia 78, Catania 95123, Italy.

Dermatoscopy and in vivo reflectance confocal microscopy are noninvasive techniques that provide a horizontal approach, with an en face view of the skin structures. Both techniques assist in the clinical diagnosis of a variety of inflammatory and infectious cutaneous disorders. In many cases, they have shown concordance. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07338635183108
Publisher Site
http://dx.doi.org/10.1016/j.det.2018.05.015DOI Listing
October 2018
21 Reads

Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid.

Clin Exp Dermatol 2019 01 20;44(1):73-75. Epub 2018 Aug 20.

Dermatology Unit, Department of Physiopathology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13718DOI Listing
January 2019
4 Reads

Therapierefraktäre Pityriasis rubra pilaris mit gutem Ansprechen auf Ustekinumab.

J Dtsch Dermatol Ges 2018 Aug;16(8):1022-1025

Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13550_gDOI Listing
August 2018
5 Reads

Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin.

JAAD Case Rep 2018 Aug 9;4(7):669-671. Epub 2018 Aug 9.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091308PMC
August 2018
3 Reads

Pityriasis Rubra Pilaris With Extensive Follicular Acantholysis Resembling Pemphigus Vulgaris: A Case Report.

Am J Dermatopathol 2019 Jan;41(1):37-39

Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine, Lebanon, NH.

Pityriasis rubra pilaris (PRP) is a rare, chronic, heterogeneous, papulosquamous inflammatory dermatosis of unknown etiology. Although erythematous scaly patches characterize the classic presentation of PRP, a broad range of clinical presentations has been reported. Histologically, PRP is characterized by psoriasiform acanthosis with alternating orthokeratosis and parakeratosis and rarely small acantholytic foci. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000372-900000000-9830
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000001222DOI Listing
January 2019
18 Reads

Nuclear Factor κB Activation in a Type V Pityriasis Rubra Pilaris Patient Harboring Multiple Variants.

Front Immunol 2018 3;9:1564. Epub 2018 Jul 3.

MTA-SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary.

Pityriasis rubra pilaris (PRP) is a rare papulosquamous skin disorder, which is phenotypically related to psoriasis. Some familial PRP cases show autosomal dominant inheritance due to mutations leading to increased nuclear factor κB (NFκB) activation. Moreover, polymorphisms have also been implicated in sporadic PRP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037727PMC
July 2018
7 Reads

Choosing the right biologic for psoriatic patients may be in the cards.

Authors:
Warren R Heymann

J Am Acad Dermatol 2018 09 30;79(3):441-442. Epub 2018 Jun 30.

Division of Dermatology, Cooper Medical School of Rowan University, Marlton, New Jersey. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183219
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.06.038DOI Listing
September 2018
14 Reads

Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab.

J Dtsch Dermatol Ges 2018 Aug 27;16(8):1022-1025. Epub 2018 Jun 27.

Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Madrid, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ddg.13550
Publisher Site
http://dx.doi.org/10.1111/ddg.13550DOI Listing
August 2018
9 Reads

A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.

Acta Derm Venereol 2018 Nov;98(10):975-976

Department of Dermatology, Kyoto University Graduate School of Medicine, 606-8507 Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-2995DOI Listing
November 2018
5 Reads

[A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].

Ann Dermatol Venereol 2018 Nov 11;145(11):665-670. Epub 2018 Jun 11.

Service de dermatologie, Universitair Ziekenhuis Brussel, (UZ Brussel), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Bruxelles, Belgique.

Background: Pityriasis rubra pilaris (PRP) is a cutaneous syndrome of unknown origin. Most cases are sporadic and acquired. Herein we report a fifth case of PRP-like eruption associated with ponatinib, a tyrosine kinase inhibitor (TKI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2018.04.009DOI Listing
November 2018
22 Reads

Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.

Cutis 2018 May;101(5):367-369

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab. Read More

View Article

Download full-text PDF

Source
May 2018
5 Reads

Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl.

JAAD Case Rep 2018 Mar 9;4(2):206-210. Epub 2018 Feb 9.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126173021
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2017.09.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993550PMC
March 2018
4 Reads

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab.

Case Rep Dermatol 2018 May-Aug;10(2):97-100. Epub 2018 May 2.

Department of Dermatology, Kepler University Hospital Linz, Linz, Austria.

Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause and often confounded with psoriasis. It is characterised by hyperkeratotic follicular papules, scaly erythematous plaques, palmoplantar keratoderma, and a progression to generalised erythroderma. Here, we report the case of a 68-year-old man with pityriasis rubra pilaris, who was successfully treated with ixekizumab, an interleukin-17A inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000488902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981592PMC
May 2018
7 Reads

Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.

Clin Exp Dermatol 2018 Dec 30;43(8):890-894. Epub 2018 May 30.

Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.

Background: Phosphoinositide 3-kinase (PI3K) inhibitors are a class of small-molecule inhibitors approved for the treatment of certain leukaemias and lymphomas. Their dermatological adverse event profile is poorly described.

Aim: To characterize a rare cutaneous adverse event from PI3K inhibitors in order to help dermatologists and oncologists identify and effectively manage such eruptions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13608DOI Listing
December 2018
21 Reads

Erythrodermic pityriasis rubra pilaris managed at home: intensive community care followed by ustekinumab.

Clin Exp Dermatol 2018 Aug 20;43(6):749-751. Epub 2018 May 20.

Department of Dermatology, Ysbyty Gwynedd, Bangor, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13626DOI Listing
August 2018
4 Reads

Recurrent Pityriasis Rubra Pilaris: A Case Report.

J Cutan Med Surg 2018 Nov/Dec;22(6):624-626. Epub 2018 May 13.

2 Pediatric Dermatology, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.

Pityriasis rubra pilaris (PRP) is an uncommon papulosquamous dermatosis characterized by follicular, erythematous, hyperkeratotic papules coalescing to salmon-coloured plaques with islands of sparing. The disease tends to be self-limited and resolves spontaneously after a few years. In some cases, the disease is persistent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418775378DOI Listing
January 2019
3 Reads

Immune-regulatory genes as possible modifiers of familial pityriasis rubra pilaris - lessons from a family with PRP and psoriasis.

J Eur Acad Dermatol Venereol 2018 Oct 24;32(10):e389-e392. Epub 2018 Jul 24.

Research Group Dermatology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jdv.15029
Publisher Site
http://dx.doi.org/10.1111/jdv.15029DOI Listing
October 2018
8 Reads

Biologics for pityriasis rubra pilaris treatment: A review of the literature.

J Am Acad Dermatol 2018 Aug 30;79(2):353-359.e11. Epub 2018 Mar 30.

Rare Disease Unit, I Dermatology Division, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy.

Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease that is often refractory to conventional therapies. The off-label use of biologics, such as anti-tumor necrosis factor, anti-interleukin (IL) 12/IL-23, and anti-IL-17 agents, has been proven successful in the past 2 decades for PRP treatment. Our aim was to analyse the literature for the use of biologics in PRP treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.036DOI Listing
August 2018
41 Reads

Recalcitrant psoriasiform dermatosis of the face: Is it related to pityriasis rubra pilaris?

J Cutan Pathol 2018 Jul 23;45(7):491-497. Epub 2018 Apr 23.

National Skin Centre, Singapore.

Background: There are patients with recalcitrant psoriasiform plaques that do not fit into conventional categories of facial dermatoses. Our study aims to describe the clinicopathological characteristics of several patients with a unique presentation of persistent psoriasiform facial rashes.

Methods: This retrospective cross-sectional study analyzed clinical and histological data of known cases of recalcitrant psoriasiform dermatosis of the face diagnosed at National Skin Centre, Singapore, over 10 years. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cup.13148
Publisher Site
http://dx.doi.org/10.1111/cup.13148DOI Listing
July 2018
19 Reads

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review.

J Am Acad Dermatol 2018 Sep 5;79(3):585-587. Epub 2018 Mar 5.

Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.02.063DOI Listing
September 2018
7 Reads

Case of pityriasis rubra pilaris with focal acantholytic dyskeratosis.

J Dermatol 2018 Sep 6;45(9):e258-e259. Epub 2018 Mar 6.

Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14286DOI Listing
September 2018
1 Read

CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.

J Am Acad Dermatol 2018 Sep 1;79(3):487-494. Epub 2018 Mar 1.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; Department of Genetics, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Electronic address:

Background: Heterozygous mutations in caspase recruitment domain family member 14 gene (CARD14) have been shown to be associated with psoriasis and familial pityriasis rubra pilaris (PRP). Many subjects with CARD14 mutations display features of both disorders, which can result in diagnostic uncertainty. In addition, these eruptions are often recalcitrant to conventional psoriasis therapies such as methotrexate, oral retinoids, and tumor necrosis factor-α inhibitors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183031
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.02.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098739PMC
September 2018
22 Reads

Erythrodermic Psoriasis in a Man with Monoclonal B-cell Lymphocytosis.

Cureus 2017 Dec 11;9(12):e1936. Epub 2017 Dec 11.

Department of Dermatology, University of California, San Diego.

Erythroderma is characterized by erythema involving greater than 90% of the body surface area and may be caused by several etiologies, including erythrodermic psoriasis. Psoriasis is an autoimmune skin and systemic condition characterized by erythematous and scaly plaques. Monoclonal B-cell lymphocytosis is an asymptomatic hematological disorder diagnosed by elevated, small, clonal B-cell counts in the peripheral blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.1936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807020PMC
December 2017
7 Reads

Pityriasis rubra pilaris: a rare inflammatory dermatosis.

BMJ Case Rep 2018 Feb 11;2018. Epub 2018 Feb 11.

Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2017-22400
Publisher Site
http://dx.doi.org/10.1136/bcr-2017-224007DOI Listing
February 2018
5 Reads

Autoinflammatory keratinization diseases: An emerging concept encompassing various inflammatory keratinization disorders of the skin.

J Dermatol Sci 2018 May 1;90(2):105-111. Epub 2018 Feb 1.

Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.

Classifying inflammatory skin diseases is challenging, especially for the expanding group of disorders triggered by genetic factors resulting in hyperactivated innate immunity that result in overlapping patterns of dermal and epidermal inflammation with hyperkeratosis. For such conditions, the umbrella term "autoinflammatory keratinization diseases" (AIKD) has been proposed. AIKD encompasses diseases with mixed pathomechanisms of autoinflammation and autoimmunity, and includes IL-36 receptor antagonist (IL-36Ra)-related pustulosis, CARD14-mediated pustular psoriasis, pityriasis rubra pilaris (PRP) type V, and familial keratosis lichenoides chronica (KLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2018.01.012DOI Listing
May 2018
9 Reads

Rapid response to cyclosporine in a rare case of pityriasis rubra pilaris with autoantibodies and systemic symptoms.

G Ital Dermatol Venereol 2018 Feb 7. Epub 2018 Feb 7.

Department of Health Sciences, A. Avogadro University of Eastern Piedmont, Novara, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.18.05906-0DOI Listing
February 2018
5 Reads

Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review.

Acta Derm Venereol 2018 Apr;98(5):501-505

Department of Dermatology, Medical University of Graz, AT-8036 Graz, Austria.

Treatment recommendations for pityriasis rubra pilaris (PRP) are based solely on case reports and small case series, as to-date no randomized controlled trials are available. We present here a case series of 3 patients and a literature review of 28 studies treating a total of 116 patients, with the aim of providing data regarding efficacy and safety of methotrexate in the treatment of PRP. Methotrexate was effective in our patients; the review showed an overall response rate of 65. Read More

View Article

Download full-text PDF

Source
http://www.medicaljournals.se/acta/content/abstract/10.2340/
Publisher Site
http://dx.doi.org/10.2340/00015555-2885DOI Listing
April 2018
16 Reads